STOCK TITAN

[Form 4] METLIFE INC Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

MetLife, Inc. (MET) non-management director Christian Stephane Mumenthaler reported acquiring 534 shares of MetLife common stock on 10/01/2025 at a price of $81.93 per share. After the transaction he beneficially owned 1,458 shares. The filing states these shares were part of director retainer fees and were deferred under the MetLife Deferred Compensation Plan for Non-Management Directors. The Form 4 was signed by an attorney-in-fact on 10/03/2025. The report reflects a routine compensation-related equity grant and deferral by a board member.

MetLife, Inc. (MET) dirigente non esecutivo Christian Stephane Mumenthaler ha riferito di aver acquisito 534 azioni delle azioni comuni MetLife il 01/10/2025 al prezzo di $81,93 per azione. Dopo la transazione deteneva in modo benefico 1.458 azioni. La dichiarazione indica che queste azioni facevano parte delle compensazioni per i compensi da direttore e sono state differite ai sensi del MetLife Deferred Compensation Plan for Non-Management Directors. Il Modulo 4 è stato firmato da un procuratore-in-fatto il 03/10/2025. Il rapporto riflette una concessione azionaria legata alla retribuzione di routine e il differimento da parte di un membro del consiglio.

MetLife, Inc. (MET) director no ejecutivo Christian Stephane Mumenthaler informó haber adquirido 534 acciones de MetLife comunes en 01/10/2025 a un precio de $81,93 por acción. Tras la operación poseía en beneficio propio 1,458 acciones. La presentación indica que estas acciones formaban parte de las comisiones por retención de directores y fueron diferidas bajo el MetLife Deferred Compensation Plan for Non-Management Directors. El Formulario 4 fue firmado por un apoderado el 03/10/2025. El informe refleja una concesión accionaria relacionada con la compensación de rutina y el diferimiento por parte de un miembro de la junta.

MetLife, Inc. (MET) 비경영진 이사 Christian Stephane Mumenthaler534주 MetLife 보통주를 2025-10-01에 주당 $81.93에 취득했다고 보고했습니다. 거래 후 그는 이익상으로 1,458주를 보유했습니다. 제출 서류는 이 주식이 이사회 보수의 일부였으며 MetLife Deferred Compensation Plan for Non-Management Directors에 따라 이연되었다고 명시합니다. Form 4는 2025-10-03에 대리인이 서명했습니다. 이 보고서는 보상의 일상적 주식 부여 및 이연을 이사회 구성원이 보인 것을 반영합니다.

MetLife, Inc. (MET) administrateur non exécutif Christian Stephane Mumenthaler a déclaré avoir acquis 534 actions ordinaires MetLife le 01/10/2025 au prix de $81,93 par action. Après la transaction, il détenait en bénéficiaire 1 458 actions. Le dépôt indique que ces actions faisaient partie des honoraires de directeur et ont été différées en vertu du MetLife Deferred Compensation Plan for Non-Management Directors. Le Formulaire 4 a été signé par un mandataire le 03/10/2025. Le rapport reflète une attribution d’actions liée à la rémunération habituelle et un report par un membre du conseil.

MetLife, Inc. (MET) nicht geschäftsführendes Vorstandsmitglied Christian Stephane Mumenthaler berichtete, 534 Aktien der MetLife-Stammaktien am 01.10.2025 zu einem Preis von $81,93 pro Aktie erworben zu haben. Nach der Transaktion besaß er rechnerisch 1.458 Aktien. Die Einreichung besagt, dass diese Aktien Teil der Direktorengebühren waren und gemäß dem MetLife Deferred Compensation Plan for Non-Management Directors aufgeschoben wurden. Das Formular 4 wurde am 03.10.2025 von einem Bevollmächtigten unterschrieben. Der Bericht spiegelt eine routinemäßige aktienbezogene Vergütungszusage und deren Aufschub durch ein Vorstandsmitglied wider.

MetLife, Inc. (MET) مدير غير تنفيذي Christian Stephane Mumenthaler أفاد بشراء 534 سهماً من أسهم MetLife العادية في 01/10/2025 بسعر $81.93 للسهم. بعد الصفقة أصبح يمتلك بشكل مستفيد 1,458 سهماً. تشير الوثيقة إلى أن هذه الأسهم كانت جزءاً من رسوم تظلّ المدير وتم تأجيلها بموجب MetLife Deferred Compensation Plan for Non-Management Directors. تم توقيع النموذج 4 من قبل وكيل بالوكالة في 03/10/2025. يعكس التقرير منحة أسهم مرتبطة بالتعويضات الروتينية والتأجيل من قبل عضو مجلس الإدارة.

MetLife, Inc. (MET) 非管理层董事 Christian Stephane Mumenthaler 报告在 2025/10/01 以每股 $81.93 的价格购买了 534 股 MetLife 普通股。交易后他受益所有权持有 1,458 股。 文件指出这些股票属于董事报酬的一部分,且根据 MetLife Deferred Compensation Plan for Non-Management Directors 予以递延。 Form 4 于 2025/10/03 由代理律师签署。该报告反映了与董事会成员相关的常规薪酬相关的股票授予及递延。

Positive
  • 534 shares acquired via deferred director compensation indicates direct share ownership by a director
  • Transaction executed through the MetLife Deferred Compensation Plan for Non-Management Directors, reflecting a formal compensation mechanism
Negative
  • None.

MetLife, Inc. (MET) dirigente non esecutivo Christian Stephane Mumenthaler ha riferito di aver acquisito 534 azioni delle azioni comuni MetLife il 01/10/2025 al prezzo di $81,93 per azione. Dopo la transazione deteneva in modo benefico 1.458 azioni. La dichiarazione indica che queste azioni facevano parte delle compensazioni per i compensi da direttore e sono state differite ai sensi del MetLife Deferred Compensation Plan for Non-Management Directors. Il Modulo 4 è stato firmato da un procuratore-in-fatto il 03/10/2025. Il rapporto riflette una concessione azionaria legata alla retribuzione di routine e il differimento da parte di un membro del consiglio.

MetLife, Inc. (MET) director no ejecutivo Christian Stephane Mumenthaler informó haber adquirido 534 acciones de MetLife comunes en 01/10/2025 a un precio de $81,93 por acción. Tras la operación poseía en beneficio propio 1,458 acciones. La presentación indica que estas acciones formaban parte de las comisiones por retención de directores y fueron diferidas bajo el MetLife Deferred Compensation Plan for Non-Management Directors. El Formulario 4 fue firmado por un apoderado el 03/10/2025. El informe refleja una concesión accionaria relacionada con la compensación de rutina y el diferimiento por parte de un miembro de la junta.

MetLife, Inc. (MET) 비경영진 이사 Christian Stephane Mumenthaler534주 MetLife 보통주를 2025-10-01에 주당 $81.93에 취득했다고 보고했습니다. 거래 후 그는 이익상으로 1,458주를 보유했습니다. 제출 서류는 이 주식이 이사회 보수의 일부였으며 MetLife Deferred Compensation Plan for Non-Management Directors에 따라 이연되었다고 명시합니다. Form 4는 2025-10-03에 대리인이 서명했습니다. 이 보고서는 보상의 일상적 주식 부여 및 이연을 이사회 구성원이 보인 것을 반영합니다.

MetLife, Inc. (MET) administrateur non exécutif Christian Stephane Mumenthaler a déclaré avoir acquis 534 actions ordinaires MetLife le 01/10/2025 au prix de $81,93 par action. Après la transaction, il détenait en bénéficiaire 1 458 actions. Le dépôt indique que ces actions faisaient partie des honoraires de directeur et ont été différées en vertu du MetLife Deferred Compensation Plan for Non-Management Directors. Le Formulaire 4 a été signé par un mandataire le 03/10/2025. Le rapport reflète une attribution d’actions liée à la rémunération habituelle et un report par un membre du conseil.

MetLife, Inc. (MET) nicht geschäftsführendes Vorstandsmitglied Christian Stephane Mumenthaler berichtete, 534 Aktien der MetLife-Stammaktien am 01.10.2025 zu einem Preis von $81,93 pro Aktie erworben zu haben. Nach der Transaktion besaß er rechnerisch 1.458 Aktien. Die Einreichung besagt, dass diese Aktien Teil der Direktorengebühren waren und gemäß dem MetLife Deferred Compensation Plan for Non-Management Directors aufgeschoben wurden. Das Formular 4 wurde am 03.10.2025 von einem Bevollmächtigten unterschrieben. Der Bericht spiegelt eine routinemäßige aktienbezogene Vergütungszusage und deren Aufschub durch ein Vorstandsmitglied wider.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Mumenthaler Christian Stephane

(Last) (First) (Middle)
METLIFE, INC.
200 PARK AVENUE

(Street)
NEW YORK NY 10166

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/01/2025 A(1) 534 A $81.93 1,458 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
Remarks:
/s/ Taylor McInerney Jansen, Attorney-in-fact 10/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MetLife director Christian Stephane Mumenthaler report on Form 4 (MET)?

He acquired 534 shares of MetLife common stock on 10/01/2025 at $81.93 per share and beneficially owned 1,458 shares after the transaction.

Why were the shares acquired by the MetLife director?

The filing states the shares were part of non-management director retainer fees and were deferred under the MetLife Deferred Compensation Plan for Non-Management Directors.

When was the Form 4 signed and filed for this transaction?

The Form 4 shows the signature by an attorney-in-fact on 10/03/2025 and reports a transaction date of 10/01/2025.

How many MetLife shares did the director own after the reported transaction?

1,458 shares were beneficially owned following the reported acquisition.

What price was paid for the MetLife shares reported on the Form 4?

The reported price per share for the acquisition was $81.93.
MetLife

NYSE:MET

MET Rankings

MET Latest News

MET Latest SEC Filings

MET Stock Data

54.76B
663.27M
0.25%
91.63%
1.37%
Insurance - Life
Life Insurance
Link
United States
NEW YORK